I agree with your POV narmac.

For what it  is worth, and I'll say very little if anything, here are my thoughts:

• Not even a hint of liquidity - pathetic!
• Zenith University still exists. Don is still a sugar daddy to the scientists.
• This was entirely a science presentation of status. Why was Don presenting. He could have given one of the bright scientists a chance too shine in the spotlight. It would help the brand image to let another light shine and show there is intellegence and integrity in the ranks.
• Don seemed subdued, almost like he had received a warning about his forward looking statements of the past year.
• Don acknowledges the huge potential value of zen3694 but he doesn't seem to know what to do about it. A seasoned business executive with biotech depth would know how to turn this into value NOW. Don seems to stare at this great science passively waiting for some sort of gift to fall from heaven.
• There was a hint of scapegoating re timelines and publications. OK I'll give him that one.
• The science is really exciting, at least to me.
• It is also fantastic that the scientist are finding ways to screen patients in order to enhance the effectivenessof zen3694.
• It is great that these well established pharmas are paying the bills.
• It appears that Newsora is leveraging this science in China to generate high brand awareness. Too bad ZCC is not doing the same in other countries then listing on the NASDAQ.
• It seems that there will be no drug approval until at least 2023 but those are Don's words so take them with a grain of salt.
• Don's BS factor started to emerge when he mentioned 'news he expected to have but can't share yet'...hahaha   :)
• My guess in the Zenith equation is that Dr Lakhotia is the unsung hero weaving together the experimental partners and it looks like the Zenith team has enough depth that others are involed.

So things look pretty good. Therefore why is there no value in ZCC? hint - D__

So here is my suggested plan. Got to have some fun here.

• ORI Capital, in concert with Hepa, should vote in Dicky To as the Chairman of the Board of Resverlogix. I believe that Hepa and ORI own about 45% of RVX so they should have a lot of sway.
• Make Don the COB emeritus.
• ORI Capital, given their broad access to biotech leaders, should recommend a CEO with biotech business depth. That way RVX can get on with funding all of the trials that should be getting done right now and shareholders would be rewarded immediately.
• Leave Zenith as is and let Don play with it until he retires. That way Don will have something to keep him busy unimpaired by shareholders. The ZCC board is entirely insiders from what I recall so Don can't be ousted at this stage and us shareholders don't count anyway.

Let's face it we have two supertanker ships full of leading science but going nowhere because the captain doesn't know where to sail. It is so sad, really.

Long and frustrated. I know we are not supposed to talk about Don but I could not ignore the elephant in the room.

Toinv